BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Terumo introduces cell & gene therapy ecosystem blueprint for APAC region

06 March 2026 | News

A collaborative integration model to enable practical, scalable cell and gene therapy delivery

Terumo Blood and Cell Technologies (Terumo BCT) has announced the launch of its new cell & gene therapy (C&GT) Ecosystem Blueprint — a practical, collaborative approach designed to help cell and gene therapy developers in the Asia-Pacific (APAC) region move from early development to scalable, repeatable delivery.

C&GT activity is accelerating across APAC, but many programmes face persistent challenges in translating scientific progress into consistent, scalable operations. These challenges include fragmented workflows, high operating costs, shortages of GMP-trained talent and variation in regulatory and manufacturing readiness among markets.

Rather than focusing on individual technologies or isolated process steps, the C&GT Ecosystem Blueprint provides a clear map of how critical capabilities, workflows and partnerships must come together — from cell collection and processing through clinical readiness — to simplify complex workflows and support more cost-efficient, scalable C&GT development and manufacturing.

Terumo BCT will be applying the blueprint in collaboration with regional partners and C&GT developers across multiple real-world use cases, including the CiRA Foundation to co-develop standardized induced pluripotent stem cell (iPSC) workflows; GenScript contributing upstream cell selection and activation technologies and EurekaBio integrating downstream processing — together enabling an integrated, end-to-end CAR-T workflow solution; and KBIOHealth and Advanced Cell Therapy and Research Institute, Singapore (ACTRIS) to address regional GMP training and implementation capabilities.

Terumo BCT designed its C&GT Ecosystem Blueprint around three core pillars: Fit-for-purpose workflows adaptable to different C&GT modalities and development stages; integrated capability and capacities that enable simplified GMP-compliant workflows, reduced variability and operational cost as programs scale; and collaborative execution models that align developers, technology providers and regional partners around shared readiness goals.